Asim Siddiqui, PhD
Chief Technology Officer
With an extensive background in bioinformatics, systems and software engineering, next-generation sequencing, and cancer and prenatal diagnostics, Asim is responsible for building and overseeing NuMedii’s highly predictive drug discovery technology platform. Before NuMedii, he was in charge of product management and bioinformatics at several leading organizations including Natera, Life Technologies, Sirius Genomics, and the Genome Sciences Centre, part of the British Columbia Cancer Agency. An inventor on several patents, he has been an author on more than 30 peer-reviewed publications including several published in Science and Nature. Asim has a PhD in Bioinformatics from Oxford University, and a BA and a MA in Physics with honors from Cambridge University.
Heather Arnett, PhD
Vice President Research
Heather is leading research discovery and development at NuMedii, successfully translating AI hits into novel therapeutics. She has more than 15 years of experience in large and small molecule drug discovery and development, and more than 30 publications in top-tier journals with research focused on diverse pathways in immunology, neuroscience, and fibrotic diseases. In her most recent role at Amgen, Heather spearheaded multiple immune modulatory therapies, as well as building and managing a robust team of scientists and associates focused on filling the pipeline with new therapies for fibrotic and inflammatory diseases, and immuno-oncology. She holds a PhD in Neuroscience from the University of North Carolina at Chapel Hill and completed a National Multiple Sclerosis Society postdoctoral fellowship at Harvard Medical School and the Dana-Farber Cancer Institute.
Linda De Young, PhD
Head, Product Development
Linda bridges the connection between technology and drug development at NuMedii. She brings 20 years’ experience leading drug development programs for industry leading and start-up biotechnology and life science companies across a variety of platforms – small molecule, protein, polymer, cellular and antisense therapeutics – as well as a range of drug delivery devices. In addition to 10 years as a principal at Virtualizing Drug Development and IND Enabling Consulting, Linda held senior leadership positions at several companies focused on cardiovascular disease and oncology including AeroGen and Genentech. Linda has a BS in Biochemistry from the UC Davis, a PhD in Pharmaceutical Chemistry from UC San Francisco, and was a Postdoctoral Fellow, Department of Chemistry and Biochemistry, UC Santa Cruz.